Tokyo, Japan

Mitsuharu Nakamura


 

Average Co-Inventor Count = 4.8

ph-index = 2

Forward Citations = 17(Granted Patents)


Location History:

  • Tokyo, JP (2010 - 2012)
  • Osaka, JP (2020)

Company Filing History:


Years Active: 2010-2020

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Mitsuharu Nakamura: Innovator in Pharmaceutical Chemistry

Introduction

Mitsuharu Nakamura is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 4 patents. His work focuses on innovative methods and compounds that have the potential to address various medical conditions.

Latest Patents

One of his latest patents is a production method for 4-alkoxy-3-(trifluoromethyl)benzyl alcohol. This invention relates to a method that achieves a high conversion ratio while strictly suppressing the production of byproducts by utilizing DIBAL as a reducing agent. Another notable patent involves amide derivatives and their medicinal use. This invention describes an amide derivative that acts as a C5a receptor antagonist, which is promising for treating diseases caused by inflammation, such as autoimmune diseases, sepsis, and various other serious conditions.

Career Highlights

Mitsuharu Nakamura is currently associated with Mitsubishi Tanabe Pharma Corporation, where he continues to innovate in the pharmaceutical sector. His work has been instrumental in developing new therapeutic agents that can significantly improve patient outcomes.

Collaborations

He has collaborated with notable coworkers, including Takao Kamahori and Seigo Ishibuchi, contributing to a dynamic research environment that fosters innovation.

Conclusion

Mitsuharu Nakamura's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a key innovator in the field. His work continues to pave the way for advancements in medical treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…